antibody-dependent cellular cytotoxicity

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to antibody-dependent cellular cytotoxicity: antibody-dependent cell-mediated cytotoxicity (ADCC)


1. the degree to which an agent has specific destructive action on certain cells.
2. the possession of such destructive action, particularly in reference to lysis of cells by immune phenomena and to antineoplastic agents that selectively kill dividing cells. adj., adj cytotox´ic.
antibody-dependent cell-mediated cytotoxicity (ADCC) (antibody-dependent cellular cytotoxicity) lysis of target cells coated with antibody by effector cells with cytolytic activity and specific immunoglobulin receptors called Fc receptors, including K cells, macrophages, and granulocytes. Lysis of the target cell is extracellular, requires direct cell-to-cell contact, and does not involve complement.
cell-mediated cytotoxicity destruction of a target cell by specific lymphocytes, such as cytotoxic T lymphocytes or NK cells; it may be antibody-dependent (see antibody-dependent cell-mediated c.) or independent, as in certain cell-mediated hypersensitivity reactions.

antibody-dependent cellular cytotoxicity



The process by which phagocytes and natural killer cells bind with receptors on antibodies to destroy the antigens to which the antibodies are bound.
See: natural killer cell
References in periodicals archive ?
Antibody-dependent cellular cytotoxicity (ADCC) activity is an important function of the human immune system, whereby immune cells can kill target cells, e.
MDX-1401 is a non-fucosylated version of the MDX-060 antibody and is enhanced for greater antibody-dependent cellular cytotoxicity (ADCC) activity, an important function of the human immune system, whereby immune cells can kill target cells.
The new preclinical data indicated that human colon cancer cells are efficiently eliminated in tested cell lines by adecatumumab, mediated by antibody-dependent cellular cytotoxicity (ADCC), irrespective of their KRAS mutation status.
Aphton plans to use BioWa's POTELLIGENT(TM) technology for the development of a next-generation Lewis Y-specific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC).
In preclinical studies, SGN-40 was found to have antitumor activity in models of chronic lymphocytic leukemia (CLL) through antibody-dependent cellular cytotoxicity (ADCC).
announced today that it has entered into a license agreement with CSL Limited, providing CSL with access to BioWa's POTELLIGENT(R) Technology platform for the research and development of antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
Nasdaq: MEDI) has licensed BioWa's POTELLIGENT(TM) technology for use in researching and developing select MedImmune antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).
12 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells.
OncoTherapy Science will employ its technology for identification of the cancer antigens and generation of Mabs against those antigens, and BioWa will apply its POTELLIGENT(TM) technology to the Mabs for the enhancement of antibody-dependent cellular cytotoxicity (ADCC).

Full browser ?